GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (LTS:0LIF) » Definitions » Cyclically Adjusted Book per Share

Ultragenyx Pharmaceutical (LTS:0LIF) Cyclically Adjusted Book per Share : $12.51 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Ultragenyx Pharmaceutical Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Ultragenyx Pharmaceutical's adjusted book value per share for the three months ended in Mar. 2024 was $1.688. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $12.51 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Ultragenyx Pharmaceutical's average Cyclically Adjusted Book Growth Rate was 2.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-06-09), Ultragenyx Pharmaceutical's current stock price is $41.046. Ultragenyx Pharmaceutical's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $12.51. Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio of today is 3.28.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Ultragenyx Pharmaceutical was 7.39. The lowest was 2.68. And the median was 3.64.


Ultragenyx Pharmaceutical Cyclically Adjusted Book per Share Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Cyclically Adjusted Book per Share Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 12.19 12.40

Ultragenyx Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.12 12.28 12.21 12.40 12.51

Competitive Comparison of Ultragenyx Pharmaceutical's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio falls into.



Ultragenyx Pharmaceutical Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ultragenyx Pharmaceutical's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.688/131.7762*131.7762
=1.688

Current CPI (Mar. 2024) = 131.7762.

Ultragenyx Pharmaceutical Quarterly Data

Book Value per Share CPI Adj_Book
201406 5.093 100.560 6.674
201409 6.259 100.428 8.213
201412 5.791 99.070 7.703
201503 9.579 99.621 12.671
201506 8.851 100.684 11.584
201509 14.857 100.392 19.502
201512 13.659 99.792 18.037
201603 12.562 100.470 16.476
201606 11.368 101.688 14.732
201609 11.382 101.861 14.725
201612 11.493 101.863 14.868
201703 11.555 102.862 14.803
201706 10.122 103.349 12.906
201709 8.604 104.136 10.888
201712 8.682 104.011 11.000
201803 14.571 105.290 18.236
201806 14.047 106.317 17.411
201809 13.112 106.507 16.223
201812 11.972 105.998 14.884
201903 15.474 107.251 19.013
201906 14.216 108.070 17.334
201909 12.593 108.329 15.319
201912 11.303 108.420 13.738
202003 10.240 108.902 12.391
202006 11.514 108.767 13.950
202009 10.954 109.815 13.145
202012 17.276 109.897 20.715
202103 15.637 111.754 18.439
202106 14.346 114.631 16.492
202109 13.738 115.734 15.642
202112 13.304 117.630 14.904
202203 11.411 121.301 12.396
202206 9.685 125.017 10.209
202209 6.690 125.227 7.040
202212 5.021 125.222 5.284
202303 3.120 127.348 3.228
202306 1.805 128.729 1.848
202309 0.439 129.860 0.445
202312 3.346 129.419 3.407
202403 1.688 131.776 1.688

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Ultragenyx Pharmaceutical  (LTS:0LIF) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=41.046/12.51
=3.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Ultragenyx Pharmaceutical was 7.39. The lowest was 2.68. And the median was 3.64.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Ultragenyx Pharmaceutical Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultragenyx Pharmaceutical (LTS:0LIF) Business Description

Traded in Other Exchanges
Address
60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Ultragenyx Pharmaceutical (LTS:0LIF) Headlines

No Headlines